Key takeaway: DMPA causes a small, reversible decline in bone mineral density (BMD) during use; routine DXA screening and an arbitrary 2-year limit are not recommended for adolescents.
Which of the following best describes the association between depot medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) loss in adolescent girls?
Answers Options:
A. Decline in bone mineral density (BMD) while on DMPA substantially reverses upon discontinuation of the drug.DMPA suppresses ovulation and lowers estradiol, leading to a modest BMD decline (~1–2% per year at spine/hip) during use, with substantial recovery after discontinuation and no clear evidence of increased fracture risk. Contemporary guidance emphasizes that while the FDA black box warning (2004) advises caution about prolonged use, expert societies do not impose a hard 2-year limit, and routine DXA monitoring in adolescents is not recommended.
Why do clinicians miss this? Boards expect you to prioritize current consensus statements over legacy label language. ACOG (Committee Opinion 602, reaffirmed 2023) and the Centers for Disease Control and Prevention U.S. Medical Eligibility Criteria (2024) state that benefits of DMPA may outweigh theoretical BMD concerns in adolescents; continuation beyond two years is acceptable when appropriate. Counseling should stress reversibility, avoid unnecessary DXA, and discuss LARC alternatives.
| Option | What It Tests / Implies | Why It’s Wrong Here |
|---|---|---|
| DMPA should not be used for more than 2 consecutive years because of the effect on bone mineral density (BMD) | Takes FDA black box as absolute duration limit | ACOG and CDC do not mandate a 2-year limit; continued use is acceptable when benefits outweigh risks. |
| A bone density scan (dual energy X-ray absorptiometry) should be obtained annually on women using DMPA because of the effect on bone mineral density (BMD). | Assumes routine monitoring is needed | Routine DXA is not recommended in adolescents on DMPA; results are hard to interpret and do not change management. |
| Adolescent girls using DMPA should be advised to take calcium and vitamin D supplements because of the effect on bone mineral density (BMD). | Implies mandatory supplementation | Encourage age-appropriate calcium/vitamin D and weight-bearing activity, but automatic supplementation solely due to DMPA is not evidence-based. |
| Adolescent girls using DMPA should be advised that they may experience a permanent decrease in bone mineral density (BMD) with use beyond 2 consecutive years. | Presumes permanent harm | BMD recovers substantially after stopping DMPA; permanent loss has not been demonstrated in adolescents. |
| Decline in bone mineral density (BMD) while on DMPA substantially reverses upon discontinuation of the drug. | Recognizes reversibility | Correct: BMD decline during DMPA use is typically modest and substantially reversible after discontinuation. |
On boards, choose “reversible BMD loss without routine DXA or a hard 2‑year stop” when counseling adolescents on DMPA.
1. Recognize that DMPA-associated BMD loss in adolescents is modest and substantially reversible upon discontinuation, with no clear fracture signal.
2. Apply guideline-based counseling: no routine DXA, no arbitrary 2-year limit, and emphasize shared decision-making and alternative methods when appropriate.
The item pits legacy FDA black box language against current practice standards. Examiners expect you to cite consensus guidance—ACOG (reaffirmed 2023) and CDC U.S. MEC (2024)—which prioritize contraceptive efficacy and patient preference while acknowledging reversible, small BMD changes.
A 16-year-old has used DMPA for 18 months and is happy with amenorrhea and contraception. Best counseling?
A. Schedule annual DXA scans until DMPA is discontinued.A 17-year-old has used DMPA for 2.5 years without issues. Next best step?
A. Discontinue immediately due to FDA black box.Which best describes typical BMD change with DMPA in adolescents?
A. 5%–8% annual hip loss, largely permanentAfter stopping DMPA, what is the expected BMD trajectory in adolescents?
A. Continued decline for years due to residual drugWhich scenario warrants DXA in an adolescent on DMPA?
A. Any DMPA use beyond 12 months
Compare counseling for a healthy 16-year-old satisfied with DMPA versus a 17-year-old athlete with a stress fracture history and low BMI considering DMPA: How do you balance reversible BMD effects, alternative methods (e.g., LARC), timing of DXA (if any), and shared decision-making?
This question appears in Med-Challenger OBGYN Review with CME
Try for free and save. Ace your exams and meet your CME/MOC requirements for just $26 a month!
No matter your program, no matter the size, Med-Challenger for Groups and Institutions can better prepare your program or group, fulfill industry requirements, and increase test scores.